Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Share-based Compensation: 2019-2021

Historic Share-based Compensation for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2021 value amounting to $3.4 million.

  • Black Diamond Therapeutics' Share-based Compensation rose 36.68% to $3.4 million in Q4 2021 from the same period last year, while for Dec 2021 it was $14.0 million, marking a year-over-year increase of 80.77%. This contributed to the annual value of $10.6 million for FY2024, which is 10.65% up from last year.
  • Per Black Diamond Therapeutics' latest filing, its Share-based Compensation stood at $3.4 million for Q4 2021, which was up 12.20% from $3.0 million recorded in Q3 2021.
  • Black Diamond Therapeutics' Share-based Compensation's 5-year high stood at $4.6 million during Q2 2021, with a 5-year trough of $91,000 in Q1 2019.
  • Its 3-year average for Share-based Compensation is $2.1 million, with a median of $2.2 million in 2020.
  • Examining YoY changes over the last 5 years, Black Diamond Therapeutics' Share-based Compensation showed a top increase of 1,962.64% in 2020 and a maximum decrease of 1.59% in 2020.
  • Over the past 3 years, Black Diamond Therapeutics' Share-based Compensation (Quarterly) stood at $2.5 million in 2019, then decreased by 1.59% to $2.5 million in 2020, then soared by 36.68% to $3.4 million in 2021.
  • Its Share-based Compensation stands at $3.4 million for Q4 2021, versus $3.0 million for Q3 2021 and $4.6 million for Q2 2021.